Skip to main content

Table 3 Cardiovascular and diabetes biochemical markers in PLWH with and without MetS

From: A cross-sectional assessment of metabolic syndrome in HIV-infected people of low socio-economic status receiving antiretroviral therapy

  MetS (n =  29) No MetS (n =  60) P value
T-Chol (mg/dl) 184 ± 41 182 ± 36 0.83
LDL-C (mg/dl) 110 ± 31 107.34 0.71
HDL-C (mg/dl) 46 ± 15 53 ± 15 0.07
VLDL-C (mg/dl) 28 ± 17 22 ± 12 0.12
Non-HDL-C (mg/dl) 138 ± 35 130 ± 38 0.32
Total/HDL-C 4.2 ± 1.1 3.7 ± 1.3 0.09
TGs (mg/dl) 139 ± 84 112 ± 56 0.13
CRP (mg/L) 6.5 ± 8.3 5.3 ± 7.3 0.52
FG (mg/dl) 103 ± 51 91 ± 10 0.21
HbA1C (%; mmol/mol)* 6.4;46 5.7;39 0.03
Insulin (μU/mL) 17.3 ± 13.1 13.4 ± 7.6 0.15
Insulin resistance (HOMA) 4.3 ± 3.4 3.0 ± 1.9 0.09
  1. Data are means ± SD. *SDs for HbA1C are 1.7 (MetS) and 0.6 (No MetS).
  2. PLWH people living with HIV, MetS metabolic syndrome, T-Chol total cholesterol, LDL-C low-density lipoprotein cholesterol, HDL-C high-density lipoprotein cholesterol, VLDL-C very-low density lipoprotein cholesterol, TGs triglycerides, CRP C-reactive protein, FG fasting glucose, HbA1C hemoglobin A1C, HOMA homeostasis model assessment.